Core Technology
Andes Biotechnologies’ core technology is composed of oligonucleotides targeting non-coding mitochondrial RNAs, focusing on cancer.
Clinical Trials
Andes Biotechnologies is currently carrying out Phase 1 trials in the United States to test the safety of Andes-1537
Intellectual Property
Andes holds over 49 issued patents (including the EU, US, Japan) covering compositions of matter and the diagnostic and therapeutic uses of non-coding mitochondrial RNAs and oligonucleotides that target the RNA
FROM PABLO VALENZUELA
Andes Biotechnologies represents the most exciting moment of my career. Our core technology could represent an important advance in the treatment of all forms of cancer. By disrupting a novel family of RNA targets of mitochondrial origin with anti-sense technology, we can selectively destroy cancerous cells with no effect on healthy cells.
This is a completely new approach to treatment and so has the potential to create a whole new class of therapeutic products.
UPDATES
Andes Biotechnologies participated in the online version of the VIII Latin American Symposium of Oncology Gastroenterology (SLAGO, in Spanish), organized by the foundation Cancer Chile. The event gathered health professionals…
Following the phase 1a trial of Andes-1537, where some preliminary signals of efficacy were observed in patients with abdominal cancer, an open, multicentric, two stage phase 1b trial was initiated…
Key points Andes-1537 is a well-tolerated drug with a novel mechanism. Maximum tolerated dose (MTD) determined to be 600 mg SQ twice weekly. Good safety profile with injection site reactions…
Merck celebrated its 350th anniversary, and its Chilean subsidiary hosted an event at the residence of the Ambassador of the Federal Republic of Germany. The motto of the evening was…
